key: cord-0935475-q4eqaecs
authors: Dal‐Ré, Rafael
title: Will AstraZeneca be able to provide clinical trial data on its COVID‐19 vaccine efficacy in older adults?
date: 2021-03-24
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14828
sha: 0d71b729fbffc40eb79a8a0df0966f742cd9eb95
doc_id: 935475
cord_uid: q4eqaecs

nan

tion, the EU label states that it was impossible to estimate the vaccine efficacy in older adults (≥56-year-olds) due to insufficient number of participants and COVID-19 cases in this population group. 2 With the information available at the time the EU granted the authorization, many EU countries decided to limit its administration to, for instance, ≤55-year-old individuals (e.g., Italy and Spain) or ≤65-year-olds (e.g., France and Germany). On February 15, the World Health Organization included this vaccine in its Emergency Use Listing for adults and the elderly, although acknowledging the lack of efficacy data in this latter population group. 3 In the first report published on December 8, 2020, Voysey et al. 

Regulatory approval of COVID-19 vaccines AstraZeneca. MHRA. Information for healthcare professionals and the public about the COVID-19 vaccine AstraZeneca. Published

COVID-19 vaccine AstraZeneca

Strategic Advisory Group of Experts) on Immunization Working Group on COVID-19 vaccines. AZD1222 vaccine against COVID-19 developed by Oxford University and Astra Zeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Swissmedic examines the data on the vaccine from AstraZeneca it receives on an ongoing basis

Trial participants' right after authorization of COVID-19 vaccines

See how the vaccine rollout is going in your state. The New York Times

Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa

Effectiveness of first dose of covid-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people